Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 96

1.

Frequency and characteristics of short versus longitudinally extensive myelitis in adults with MOG antibodies: A retrospective multicentric study.

Ciron J, Cobo-Calvo A, Audoin B, Bourre B, Brassat D, Cohen M, Collongues N, Deschamps R, Durand-Dubief F, Laplaud D, Maillart E, Papeix C, Zephir H, Bereau M, Brochet B, Carra-Dallière C, Derache N, Gagou-Scherer C, Henry C, Kerschen P, Mathey G, Maubeuge N, Maurousset A, Montcuquet A, Moreau T, Prat C, Taithe F, Thouvenot E, Tourbah A, Rollot F, Vukusic S, Marignier R.

Mult Scler. 2019 May 31:1352458519849511. doi: 10.1177/1352458519849511. [Epub ahead of print]

PMID:
31148523
2.

Neuraxial analgesia is not associated with an increased risk of post-partum relapses in MS.

Lavie C, Rollot F, Durand-Dubief F, Marignier R, Ionescu I, Casey R, Moreau T, Tourniaire P, Hutchinson M, D'Hooghe MB, Laplaud DA, Clavelou P, De Sèze J, Debouverie M, Brassat D, Pelletier J, Lebrun-Frenay C, Le Page E, Castelnovo G, Berger E, Hautecoeur P, Heinzlef O, Durelli L, Clerico M, Trojano M, Patti F, Vukusic S; PRIMS and POPARTMUS investigators.

Mult Scler. 2019 Apr;25(4):591-600. doi: 10.1177/1352458518763080. Epub 2018 Mar 20.

PMID:
31081475
3.

CLIPPERS and its mimics: evaluation of new criteria for the diagnosis of CLIPPERS.

Taieb G, Mulero P, Psimaras D, van Oosten BW, Seebach JD, Marignier R, Pico F, Rigau V, Ueno Y, Duflos C, Fominykh V, Guiraud V, Lebrun-Frénay C, Camdessanché JP, Kerschen P, Ahle G, Téllez N, Rovira A, Hoang-Xuan K, Pelletier J, Labauge P; in cooperation with the French CLIPPERS group.

J Neurol Neurosurg Psychiatry. 2019 May 9. pii: jnnp-2018-318957. doi: 10.1136/jnnp-2018-318957. [Epub ahead of print]

PMID:
31072955
4.

Spontaneous multiple cervical artery dissections after alemtuzumab.

Durand-Dubief F, Marignier R, Berthezene Y, Cottin J, Nighoghossian N, Vukusic S.

Mult Scler. 2019 May 9:1352458519828663. doi: 10.1177/1352458519828663. [Epub ahead of print]

PMID:
31070502
5.

Pathologic and MRI analysis in acute atypical inflammatory demyelinating lesions.

Ayrignac X, Rigau V, Lhermitte B, Vincent T, de Champfleur NM, Carra-Dalliere C, Charif M, Collongues N, de Seze J, Hebbadj S, Ahle G, Oesterlé H, Cotton F, Durand-Dubief F, Marignier R, Vukusic S, Taithe F, Cohen M, Guennoc AM, Kerbrat A, Edan G, Carsin-Nicol B, Allou T, Sablot D, Thouvenot E, Ruet A, Magy L, Boncoeur-Martel MP, Labauge P, Kremer S.

J Neurol. 2019 Apr 23. doi: 10.1007/s00415-019-09328-7. [Epub ahead of print]

PMID:
31016376
6.

Aquaporin 4 distribution in the brain and its relevance for the radiological appearance of neuromyelitis optica spectrum disease.

Ameli R, R G Guttmann C, Prieto JC, Rollot F, Palotai M, Vukusic S, Marignier R, Cotton F; Group Members for OFSEP Imaging Working, COPIL of OFSEP, the NOMADMUS study group.

J Neuroradiol. 2019 Apr 11. pii: S0150-9861(18)30337-7. doi: 10.1016/j.neurad.2019.03.015. [Epub ahead of print]

PMID:
30981824
7.

Myelin oligodendrocyte glycoprotein antibody associated disease: about the importance of diagnostic assays and selection of the target population in retrospective studies.

Cobo-Calvo A, Ruiz A, Marignier R.

Eur J Neurol. 2019 May;26(5):e58-e59. doi: 10.1111/ene.13896. No abstract available.

PMID:
30980491
8.

Paraneoplastic neuromyelitis optica and ovarian teratoma: A case series.

Bernard-Valnet R, Cobo-Calvo A, Siegfried A, Marasescu R, Bonnan M, Ballan G, Ellie E, Bauer J, Uro-Coste E, Marignier R, Brassat D.

Mult Scler Relat Disord. 2019 Jun;31:97-100. doi: 10.1016/j.msard.2019.03.031. Epub 2019 Apr 1.

PMID:
30954932
9.

Cranial nerve involvement in patients with MOG antibody-associated disease.

Cobo-Calvo A, Ayrignac X, Kerschen P, Horellou P, Cotton F, Labauge P, Vukusic S, Deiva K, Serguera C, Marignier R.

Neurol Neuroimmunol Neuroinflamm. 2019 Feb 1;6(2):e543. doi: 10.1212/NXI.0000000000000543. eCollection 2019 Mar.

10.

Clinical spectrum of central nervous system myelin oligodendrocyte glycoprotein autoimmunity in adults.

Cobo-Calvo A, Vukusic S, Marignier R.

Curr Opin Neurol. 2019 Jun;32(3):459-466. doi: 10.1097/WCO.0000000000000681.

PMID:
30762607
11.

Correction to: Usefulness of MOG-antibody titres at first episode to predict the future clinical course in adults.

Cobo-Calvo A, Sepúlveda M, d'Indy H, Armangué T, Ruiz A, Maillart E, Papeix C, Audoin B, Zephir H, Biotti D, Ciron J, Durand-Dubief F, Collongues N, Ayrignac X, Labauge P, Thouvenot E, Montcuquet A, Deschamps R, Solà-Valls N, Llufriu S, Blanco Y, de Seze J, Vukusic S, Saiz A, Marignier R; OFSEP Group; REEM Group.

J Neurol. 2019 Apr;266(4):816. doi: 10.1007/s00415-019-09215-1.

PMID:
30759286
12.

Area postrema syndrome: Another feature of anti-GFAP encephalomyelitis.

Ciron J, Sourdrille F, Biotti D, Tchoumi T, Ruiz A, Bernard-Valnet R, Maubeuge N, Marignier R.

Mult Scler. 2019 Jan 21:1352458518817992. doi: 10.1177/1352458518817992. [Epub ahead of print]

PMID:
30663514
13.

A proliferation-inducing ligand-mediated anti-inflammatory response of astrocytes in multiple sclerosis.

Baert L, Benkhoucha M, Popa N, Ahmed MC, Manfroi B, Boutonnat J, Sturm N, Raguenez G, Tessier M, Casez O, Marignier R, Ahmadi M, Broisat A, Ghezzi C, Rivat C, Sonrier C, Hahne M, Baeten D, Vives RR, Lortat-Jacob H, Marche PN, Schneider P, Lassmann HP, Boucraut J, Lalive PH, Huard B.

Ann Neurol. 2019 Mar;85(3):406-420. doi: 10.1002/ana.25415. Epub 2019 Feb 4.

PMID:
30635946
14.

Usefulness of MOG-antibody titres at first episode to predict the future clinical course in adults.

Cobo-Calvo A, Sepúlveda M, d'Indy H, Armangué T, Ruiz A, Maillart E, Papeix C, Audoin B, Zephir H, Biotti D, Ciron J, Durand-Dubief F, Collongues N, Ayrignac X, Labauge P, Thouvenot E, Montcuquet A, Deschamps R, Solà-Valls N, Llufriu S, Blanco Y, de Seze J, Vukusic S, Saiz A, Marignier R; OFSEP Group; REEM Group.

J Neurol. 2019 Apr;266(4):806-815. doi: 10.1007/s00415-018-9160-9. Epub 2019 Jan 3. Erratum in: J Neurol. 2019 Feb 7;:.

PMID:
30607536
15.

Unusual presentations of MOG antibody-associated central nervous system demyelination: Expanding the spectrum.

Marignier R.

Mult Scler. 2019 Jan;25(1):128-129. doi: 10.1177/1352458518804127. Epub 2018 Oct 31. No abstract available.

PMID:
30379124
16.

Case Report: Acute Transverse Myelitis after Zika Virus Infection.

Neri VC, Xavier MF, Barros PO, Melo Bento C, Marignier R, Papais Alvarenga R.

Am J Trop Med Hyg. 2018 Dec;99(6):1419-1421. doi: 10.4269/ajtmh.17-0938.

PMID:
30277201
17.

"Myelitis migrans": A rare cause of treatable myelitis.

Jaulent P, Pegat A, Grosset-Janin C, Durand-Dubief F, Vukusic S, Marignier R.

Rev Neurol (Paris). 2018 Dec;174(10):745-747. doi: 10.1016/j.neurol.2017.12.005. Epub 2018 Aug 22. No abstract available.

PMID:
30143322
18.

Lower frequency of antibodies to MOG in Brazilian patients with demyelinating diseases: An ethnicity influence?

Papais-Alvarenga RM, Neri VC, de Araújo E Araújo ACR, da Silva EB, Alvarenga MP, Pereira ABCNDG, Brandão AC, Alvarenga-Filho H, Guimarães MPM, Marignier R, Barros PO, Bento CM, Vasconcelos CCF.

Mult Scler Relat Disord. 2018 Oct;25:87-94. doi: 10.1016/j.msard.2018.07.026. Epub 2018 Jul 17.

PMID:
30056361
19.

Acute idiopathic optic neuritis: not always benign.

Deschamps R, Gueguen A, Lecler A, Lecouturier K, Lamirel C, Bensa C, Marignier R, Vignal C, Gout O.

Eur J Neurol. 2018 Nov;25(11):1378-1383. doi: 10.1111/ene.13753. Epub 2018 Aug 16.

PMID:
30004610
20.

Myelin oligodendrocyte glycoprotein-positive optic neuritis masquerading as pseudotumor cerebri at presentation.

Lotan I, Brody J, Hellmann MA, Bialer O, Ganelin-Cohen E, Michaeli N, Marignier R, Stiebel-Kalish H.

J Neurol. 2018 Sep;265(9):1985-1988. doi: 10.1007/s00415-018-8956-y. Epub 2018 Jun 25.

PMID:
29938337
21.

Unusual neurologic presentation of aseptic abscesses syndrome.

Nicolas P, Guerrier O, Benoit A, Durand-Dubief F, Raverot G, Debarbieux S, Delteil C, Vasiljevic A, Jouanneau E, Cotton F, Marignier R, Vukusic S.

Neurol Neuroimmunol Neuroinflamm. 2018 Jun 5;5(4):e469. doi: 10.1212/NXI.0000000000000469. eCollection 2018 Jul. No abstract available.

22.

Only Follow-Up of Memory B Cells Helps Monitor Rituximab Administration to Patients with Neuromyelitis Optica Spectrum Disorders.

Lebrun C, Cohen M, Rosenthal-Allieri MA, Bresch S, Benzaken S, Marignier R, Seitz-Polski B, Ticchioni M.

Neurol Ther. 2018 Dec;7(2):373-383. doi: 10.1007/s40120-018-0101-4. Epub 2018 Jun 7.

23.

Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults: The MOGADOR study.

Cobo-Calvo A, Ruiz A, Maillart E, Audoin B, Zephir H, Bourre B, Ciron J, Collongues N, Brassat D, Cotton F, Papeix C, Durand-Dubief F, Laplaud D, Deschamps R, Cohen M, Biotti D, Ayrignac X, Tilikete C, Thouvenot E, Brochet B, Dulau C, Moreau T, Tourbah A, Lebranchu P, Michel L, Lebrun-Frenay C, Montcuquet A, Mathey G, Debouverie M, Pelletier J, Labauge P, Derache N, Coustans M, Rollot F, De Seze J, Vukusic S, Marignier R; OFSEP and NOMADMUS Study Group.

Neurology. 2018 May 22;90(21):e1858-e1869. doi: 10.1212/WNL.0000000000005560. Epub 2018 Apr 25.

PMID:
29695592
24.

Recommendations for the use of Rituximab in neuromyelitis optica spectrum disorders

Ciron J, Audoin B, Bourre B, Brassat D, Durand-Dubief F, Laplaud D, Maillart E, Papeix C, Vukusic S, Zephir H, Marignier R, Collongues N; NOMADMUS group, under the aegis of OFSEP, SFSEP.

Rev Neurol (Paris). 2018 Apr;174(4):255-264. doi: 10.1016/j.neurol.2017.11.005. Epub 2018 Mar 30. Review.

PMID:
29606320
25.

Treatment of neuromyelitis optica with rituximab: a 2-year prospective multicenter study.

Cabre P, Mejdoubi M, Jeannin S, Merle H, Plumelle Y, Cavillon G, Smadja D, Marignier R; Francophone Society of Multiple Sclerosis and OFSEP investigators.

J Neurol. 2018 Apr;265(4):917-925. doi: 10.1007/s00415-018-8771-5. Epub 2018 Feb 17.

PMID:
29455361
26.

CLIPPERS mimickers: relapsing brainstem encephalitis associated with anti-MOG antibodies.

Berzero G, Taieb G, Marignier R, Younan N, Savatovsky J, Leclercq D, Psimaras D.

Eur J Neurol. 2018 Feb;25(2):e16-e17. doi: 10.1111/ene.13483. No abstract available.

PMID:
29356261
27.

Disease Course and Treatment Responses in Children With Relapsing Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease.

Hacohen Y, Wong YY, Lechner C, Jurynczyk M, Wright S, Konuskan B, Kalser J, Poulat AL, Maurey H, Ganelin-Cohen E, Wassmer E, Hemingway C, Forsyth R, Hennes EM, Leite MI, Ciccarelli O, Anlar B, Hintzen R, Marignier R, Palace J, Baumann M, Rostásy K, Neuteboom R, Deiva K, Lim M.

JAMA Neurol. 2018 Apr 1;75(4):478-487. doi: 10.1001/jamaneurol.2017.4601.

28.

Treating asymptomatic bacteriuria before immunosuppressive therapy during multiple sclerosis: Should we do it?

Rouzaud C, Hautecoeur P, Donze C, Heinzlef O, Dinh A; Club Francophone de la Sclérose en Plaque, Creange A, Abdullatif A, Audouin B, Tourbah A, Berger E, Bourre B, Brochet B, Mekies C, Cabre P, Papeix C, Casez O, Brassat D, Defer G, Derache N, De Seze J, Dive D, LePage E, Fromont A, Gouider R, Edan G, Pelletier J, Grimaud J, Guennoc AM, Camdessanché JP, Kwiatkowski A, Laplaud D, Lebrun C, Debouverie M, Coustans M, Gout O, La Rochelle OA, Heinzlef O, Ouallet JC, Cavelou P, Hautecoeur P, Labauge P, Vermersch P, Wiertlewski S, Vukusic S, Marignier R, Schluep M, Seeldrayers P, Slassi I, Stankoff B, Thaite F, Moreau T, Thouvenot E, Zephir H, Ciron J, Collongues N, Kerschen P, Cohen M, Gueguen A, Mathey G, Carra C, Bernady P, Faucheux JM, Planque E, Donze C, Ruet A, Mouzawakh C, Pittion S.

Mult Scler Relat Disord. 2017 Nov;18:161-163. doi: 10.1016/j.msard.2017.08.009. Epub 2017 Aug 24. No abstract available.

PMID:
29141801
29.

MOG antibody-associated optic neuritis in the setting of acute CMV infection.

Rusescu BV, Diederich NJ, Tsobo C, Marignier R, Kerschen P.

J Neurol Sci. 2017 Nov 15;382:44-46. doi: 10.1016/j.jns.2017.09.011. Epub 2017 Sep 9. No abstract available.

30.

Central nervous system Aquaporin4 autoimmunity revealed by a single pseudotumoral encephalic lesion.

Fargeot G, Aboab J, Savatovsky J, Marignier R, Lecler A, Gout O.

Metab Brain Dis. 2018 Feb;33(1):353-355. doi: 10.1007/s11011-017-0141-y. Epub 2017 Oct 31.

PMID:
29090380
31.

MOG antibody-related disorders: common features and uncommon presentations.

Cobo-Calvo Á, Ruiz A, D'Indy H, Poulat AL, Carneiro M, Philippe N, Durand-Dubief F, Deiva K, Vukusic S, Desportes V, Marignier R.

J Neurol. 2017 Sep;264(9):1945-1955. doi: 10.1007/s00415-017-8583-z. Epub 2017 Aug 2.

PMID:
28770374
32.

Decrease of blood anti-α1,3 Galactose Abs levels in multiple sclerosis (MS) and clinically isolated syndrome (CIS) patients.

Le Berre L, Rousse J, Gourraud PA, Imbert-Marcille BM, Salama A, Evanno G, Semana G, Nicot A, Dugast E, Guérif P, Adjaoud C, Freour T, Brouard S, Agbalika F, Marignier R, Brassat D, Laplaud DA, Drouet E, Van Pesch V, Soulillou JP.

Clin Immunol. 2017 Jul;180:128-135. doi: 10.1016/j.clim.2017.05.006. Epub 2017 May 18.

33.

Expansion of IL-6+ Th17-like cells expressing TLRs correlates with microbial translocation and neurological disabilities in NMOSD patients.

Barros PO, Dias ASO, Kasahara TM, Ornelas AMM, Aguiar RS, Leon SA, Ruiz A, Marignier R, Araújo ACRA, Alvarenga R, Bento CAM.

J Neuroimmunol. 2017 Jun 15;307:82-90. doi: 10.1016/j.jneuroim.2017.04.001. Epub 2017 Apr 7.

PMID:
28495144
34.

Disruption of the leptomeningeal blood barrier in neuromyelitis optica spectrum disorder.

Asgari N, Flanagan EP, Fujihara K, Kim HJ, Skejoe HP, Wuerfel J, Kuroda H, Kim SH, Maillart E, Marignier R, Pittock SJ, Paul F, Weinshenker BG.

Neurol Neuroimmunol Neuroinflamm. 2017 Apr 21;4(4):e343. doi: 10.1212/NXI.0000000000000343. eCollection 2017 Jul.

35.

Multiple sclerosis broke my heart.

Androdias G, Bernard E, Biotti D, Collongues N, Durand-Dubief F, Pique J, Sanchez I, Delmas C, Ninet J, Marignier R, Vukusic S.

Ann Neurol. 2017 May;81(5):754-758. doi: 10.1002/ana.24935. Epub 2017 May 9.

PMID:
28437859
36.

Neuromyelitis optica and neuromyelitis optica spectrum disorders.

Marignier R, Cobo Calvo A, Vukusic S.

Curr Opin Neurol. 2017 Jun;30(3):208-215. doi: 10.1097/WCO.0000000000000455. Review.

PMID:
28306572
37.

Retinal Nerve Fiber Layer May Be Better Preserved in MOG-IgG versus AQP4-IgG Optic Neuritis: A Cohort Study.

Stiebel-Kalish H, Lotan I, Brody J, Chodick G, Bialer O, Marignier R, Bach M, Hellmann MA.

PLoS One. 2017 Jan 26;12(1):e0170847. doi: 10.1371/journal.pone.0170847. eCollection 2017.

38.

Effectiveness of mycophenolate mofetil as first-line therapy in AQP4-IgG, MOG-IgG, and seronegative neuromyelitis optica spectrum disorders.

Montcuquet A, Collongues N, Papeix C, Zephir H, Audoin B, Laplaud D, Bourre B, Brochet B, Camdessanche JP, Labauge P, Moreau T, Brassat D, Stankoff B, de Seze J, Vukusic S, Marignier R; NOMADMUS study group and the Observatoire Français de la Sclérose en Plaques (OFSEP).

Mult Scler. 2017 Sep;23(10):1377-1384. doi: 10.1177/1352458516678474. Epub 2016 Nov 25.

PMID:
27885065
39.

Rituximab versus fingolimod after natalizumab in multiple sclerosis: Also consider progressive multifocal leukoencephalopathy risk.

Marignier R, Durand-Dubief F, du Pasquier R, Vukusic S.

Ann Neurol. 2016 Nov;80(5):791. doi: 10.1002/ana.24768. Epub 2016 Sep 15. No abstract available.

PMID:
27554031
40.

History of multiple sclerosis in 2 successive pregnancies: A French and Italian cohort.

Benoit A, Durand-Dubief F, Amato MP, Portaccio E, Casey R, Roggerone S, Androdias G, Gignoux L, Ionescu I, Marrosu MG, Cocco E, Ghezzi A, Annovazzi P, Trojano M, Simone M, Marignier R, Confavreux C, Vukusic S.

Neurology. 2016 Sep 27;87(13):1360-7. doi: 10.1212/WNL.0000000000003036. Epub 2016 Jul 27.

PMID:
27466470
41.

Neuromyelitis Optica Spectrum Disorder: Disease Course and Long-Term Visual Outcome.

Brody J, Hellmann MA, Marignier R, Lotan I, Stiebel-Kalish H.

J Neuroophthalmol. 2016 Dec;36(4):356-362.

PMID:
27348750
42.

Neuromyelitis optica study model based on chronic infusion of autoantibodies in rat cerebrospinal fluid.

Marignier R, Ruiz A, Cavagna S, Nicole A, Watrin C, Touret M, Parrot S, Malleret G, Peyron C, Benetollo C, Auvergnon N, Vukusic S, Giraudon P.

J Neuroinflammation. 2016 May 18;13(1):111. doi: 10.1186/s12974-016-0577-8.

43.

Multicentre comparison of a diagnostic assay: aquaporin-4 antibodies in neuromyelitis optica.

Waters P, Reindl M, Saiz A, Schanda K, Tuller F, Kral V, Nytrova P, Sobek O, Nielsen HH, Barington T, Lillevang ST, Illes Z, Rentzsch K, Berthele A, Berki T, Granieri L, Bertolotto A, Giometto B, Zuliani L, Hamann D, van Pelt ED, Hintzen R, Höftberger R, Costa C, Comabella M, Montalban X, Tintoré M, Siva A, Altintas A, Deniz G, Woodhall M, Palace J, Paul F, Hartung HP, Aktas O, Jarius S, Wildemann B, Vedeler C, Ruiz A, Leite MI, Trillenberg P, Probst M, Saschenbrecker S, Vincent A, Marignier R.

J Neurol Neurosurg Psychiatry. 2016 Sep;87(9):1005-15. doi: 10.1136/jnnp-2015-312601. Epub 2016 Apr 25.

44.

Clinical features and prognostic factors of spinal cord sarcoidosis: a multicenter observational study of 20 BIOPSY-PROVEN patients.

Durel CA, Marignier R, Maucort-Boulch D, Iwaz J, Berthoux E, Ruivard M, André M, Le Guenno G, Pérard L, Dufour JF, Turcu A, Antoine JC, Camdessanche JP, Delboy T, Sève P.

J Neurol. 2016 May;263(5):981-990. doi: 10.1007/s00415-016-8092-5. Epub 2016 Mar 23.

PMID:
27007482
45.

False positivity of anti aquaporin-4 antibodies in natalizumab-treated patients.

Cohen M, De Sèze J, Marignier R, Lebrun C.

Mult Scler. 2016 Aug;22(9):1231-4. doi: 10.1177/1352458516630823. Epub 2016 Feb 11.

PMID:
26869528
46.

Myelin injury without astrocytopathy in neuroinflammatory disorders with MOG antibodies.

Kaneko K, Sato DK, Nakashima I, Nishiyama S, Tanaka S, Marignier R, Hyun JW, Oliveira LM, Reindl M, Seifert-Held T, Sepulveda M, Siritho S, Waters PJ, Kurosawa K, Akaishi T, Kuroda H, Misu T, Prayoonwiwat N, Berger T, Saiz A, Kim HJ, Nomura K, Callegaro D, Fujihara K, Aoki M.

J Neurol Neurosurg Psychiatry. 2016 Nov;87(11):1257-1259. doi: 10.1136/jnnp-2015-312676. Epub 2016 Jan 22. No abstract available.

PMID:
26800711
47.

Status of diagnostic approaches to AQP4-IgG seronegative NMO and NMO/MS overlap syndromes.

Juryńczyk M, Weinshenker B, Akman-Demir G, Asgari N, Barnes D, Boggild M, Chaudhuri A, D'hooghe M, Evangelou N, Geraldes R, Illes Z, Jacob A, Kim HJ, Kleiter I, Levy M, Marignier R, McGuigan C, Murray K, Nakashima I, Pandit L, Paul F, Pittock S, Selmaj K, de Sèze J, Siva A, Tanasescu R, Vukusic S, Wingerchuk D, Wren D, Leite I, Palace J.

J Neurol. 2016 Jan;263(1):140-9. doi: 10.1007/s00415-015-7952-8. Epub 2015 Nov 3.

48.

Prediction of disease severity in neuromyelitis optica by the levels of interleukin (IL)-6 produced during remission phase.

Barros PO, Cassano T, Hygino J, Ferreira TB, Centurião N, Kasahara TM, Andrade RM, Linhares UC, Andrade AF, Vasconcelos CC, Alvarenga R, Marignier R, Bento CA.

Clin Exp Immunol. 2016 Mar;183(3):480-9. doi: 10.1111/cei.12733. Epub 2015 Dec 1.

49.

Antibodies to aquaporin-1 are not present in neuromyelitis optica.

Schanda K, Waters P, Holzer H, Aboulenein-Djamshidian F, Leite MI, Palace J, Vukusic S, Marignier R, Berger T, Reindl M.

Neurol Neuroimmunol Neuroinflamm. 2015 Oct 1;2(6):e160. doi: 10.1212/NXI.0000000000000160. eCollection 2015 Dec. No abstract available.

50.

Efficacy of rituximab in refractory neuromyelitis optica.

Collongues N, Brassat D, Maillart E, Labauge P, Ouallet JC, Carra-Dalliere C, Moreau T, Bourre B, Papeix C, Brochet B, Audoin B, Vukusic S, de Seze J, Marignier R; OFSEP and CFSEP.

Mult Scler. 2016 Jun;22(7):955-9. doi: 10.1177/1352458515602337. Epub 2015 Sep 11.

PMID:
26362900

Supplemental Content

Loading ...
Support Center